Man Group PLC Adc Therapeutics Sa Transaction History

Man Group PLC

  • $35.6 Billion
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$2.87 - $5.24 $472,703 - $863,054
164,705 Added 1543.19%
175,378 $673,000
Q3 2022

Nov 14, 2022
BUY
$4.66 - $10.31 $49,736 - $110,038
10,673 New
10,673 $51,000
Q4 2021

Feb 14, 2022
SELL
$19.29 - $31.51 $382,192 - $624,307
-19,813 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$20.45 - $30.0 $405,175 - $594,390
19,813 New
19,813 $538,000

Others Institutions Holding ADCT

# of Institutions
85
Shares Held
53.5M
Call Options Held
28K
Put Options Held
60.4K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $124M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email